Biocompatibility of human umbilical cord mesenchymal stem cells and acellular muscle bioscaffolds

doi:10.3969/j.issn.2095-4344.2013.25.008

Abstract

Abstract:

BACKGROUND: Acellular muscle bioscaffold combined with human umbilical cord mesenchymal stem cell transplantation is an important method for the treatment of spinal cord injury. But the compatibility between acellular muscle bioscaffolds and human umbilical cord mesenchymal stem cells, and whether the human umbilical cord mesenchymal stem cells can distribute evenly in the acellular muscle bioscaffolds have not been confirmed.
OBJECTIVE: To observe the compatibility of acellular muscle bioscaffolds and human umbilical cord mesenchymal stem cells.
METHODS: The rat acellular muscle bioscaffolds were prepared with improved chemical method, and the passage 3 human umbilical cord mesenchymal stem cells were divided into three groups after labeled with Hoechest33342: cell+scaffold group, cell+scaffold in vivo group and cell group. The morphology of the acellular muscle bioscaffolds was observed with hematoxylin-eosin staining and Masson staining, and the adsorption and growth conditions of human umbilical cord mesenchymal stem cells were observed under fluorescence inverted phase contrast microscope and scanning electron microscope.
RESULTS AND CONCLUSION: The human umbilical cord mesenchymal stem cells were fully attached to and actively grew on the acellular muscle bioscaffold, and distributed evenly. There was no significant difference in the number of human umbilical cord mesenchymal stem cells between the cell+scaffold in vivo group and cell+scaffold group at 1-7 days after transplantation (P > 0.05). At the 14 days after transplantation, the number of human umbilical cord mesenchymal stem cells in the cell+scaffold in vivo group was larger than that in the cell+scaffold group (P < 0.05). There is a good compatibility between human umbilical cord mesenchymal stem cells and acellular muscle bioscaffold, and the in vivo environment is more conducive to cell proliferation and integration of cells and scaffolds.

Key words: biomaterials, material biocompatibility, bioscaffold, muscle basal lamina, fluorescence labeling, compatibility, tissue engineering, other grants-supported paper

CLC Number:

R318

Zhang Tao, Wen Yi-min, Li Han, Wei Xiang-ke. Biocompatibility of human umbilical cord mesenchymal stem cells and acellular muscle bioscaffolds [J]. Chinese Journal of Tissue Engineering Research, 2013, 17(25): 4616-4622.

Figures/Tables 5

References

[1] Heldner MR, Arnold M, Nedeltchev K, et al. Vascular Diseases of the Spinal Cord: A Review. Curr Treat Options Neurol. 2012;14(6):509-520.

[2] Fehlings MG, Tighe A. Spinal Cord Injury: The Promise of Translational Research. Neurosurg Focus. 2008;25(5):1.

[3] Li L, Lü G, Wang YF, et al. Glial cell-derived neurotrophic factor mRNA expression in a rat model of spinal cord injury following bone marrow stromal cell transplantation. Neural Regen Res 2008;3(10):1056-1059.

[4] Han MY, Feng SQ, Li H, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2010;14(19):3483-3489.韩明远, 冯世庆, 李辉, 等. 移植人脐带间充质干细胞修复大鼠脊髓损伤[J]. 中国组织工程研究与临床康复, 2010,14(19): 3483-3489.

[5] Zou J, Gan MF, Zhu XS, et al. Protective effects of human umbilical cord mesenchymal stem cell vein transplantation against spinal cord ischemia/reperfusion injury in rats. Neural Regener Res.2010;5(3):7.

[6] Guo YW, Ke YQ, Li M, et al. Human Umbilical Cord-Derived Schwann-Like Cell Transplantation Combined with Neurotrophin-3 Administration in Dyskinesia of Rats with Spinal Cord Injury. Neurochem Res. 2011;36(5):783-792.

[7] Han MY. Tianjin Yike Daxue. 2010.韩明远. 不同途径移植人脐带间充质干细胞修复大鼠脊髓损伤的研究[D]. 天津医科大学，2010.

[8] Wang XH, Shen YX, Fan ZH, et al. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(25): 4719-4722.王新宏, 沈忆新, 范志海, 等. 组织工程支架材料在脊髓损伤修复中的应用[J]. 中国组织工程研究与临床康复, 2011,15(25): 4719-4722.

[9] Xue H, Chen D, Zhang XY, et al. Xi′an Jiaotong Daxue Xuebao. 2009;30(2):5.薛辉, 陈东, 张秀英, 等. 化学去细胞肌肉促进大鼠脊髓半横断后的轴突再生[J]. 西安交通大学学报,2009,30(2):5.

[10] The Ministry of Science and Technology of the People's Republic of china.Guidance Suggestions for the Care and Use of Laboratory Animals. 2009.

[11] Xiao HT, Niu XH, Liu Y. Zhengzhou Daxue Xuebao. 2010; 45(2):4.肖宏涛, 牛希华, 刘毅. 人脐带间充质干细胞的体外分离、培养及诱导分化[J]. 郑州大学学报,2010,45(2):4.

[12] Liu Y, Xiao HT. Zhonghua Yixue Meixue Meirong Zazhi. 2010; 16(1):4.刘毅,肖宏涛.人脐带间充质干细胞与蚕丝素多孔支架的体外复合培养[J]. 中华医学美学美容杂志,2010,16(1):4.

[13] Mligiliche N, Kitada M, Ide C. Grafting of detergent-denatured skeletal muscles provides effective conduits for extension of regenerating axons in the rat sciatic nerve. Arch Histol Cytol. 2001;64(1):29-36.

[14] Arai T, Kanje M, Lundborg G, et al. Axonal outgrowth in muscle grafts made acellular by chemical extraction. Restor Neurol Neurosci. 2000;17(4):165-174.

[15] Wei XK, Wen YM, Li H, et al. Zhongguo Jiaoxing Waike Zazhi. 2012;(20):1874-1877.魏祥科, 文益民, 李含, 等. 骨髓间充质干细胞与去细胞肌肉生物支架体外相容性研究[J]. 中国矫形外科杂志, 2012, (20): 1874-1877.

[16] Zhang XY, Xue H, Liu JM, et al. Chemically extracted acellular muscle: A new potential scaffold for spinal cord injury repair. J Biomed Mater Res A. 2012;100A(3):578-587.

[17] Li PJ, Xu ST. Zhongguo Jizhu Jisui Zazhi. 2000;10(4):5.李培建, 胥少汀. 肌基膜管移植及神经生长因子对脊髓横断性损伤的修复作用[J]. 中国脊柱脊髓杂志,2000,10(4):5.

[18] Guo SZ, Ren XJ, Wu B, et al. Preparation of the acellular scaffold of the spinal cord and the study of biocompatibility. Spinal Cord. 2010;48(7):576-581.

[19] Yin WH, Lu KW, Jin DD. Morphology of spinal cord extracellular matrix-derived acellular scaffolds fabricated in rats. Neural Regen Res. 2011;6(10):767-771.

[20] Fehlings MG, Vawda R. Cellular Treatments for Spinal Cord Injury: The Time is Right for Clinical Trials. Neurotherapeutics. 2011;8(4):704-720.

[21] Bajada S, Mazakova I, Richardson JB, et al. Updates on stem cells and their applications in regenerative medicine. J Tissue Eng Regen Med. 2008;2(4):169-183.

[22] Wong RSY. Mesenchymal Stem Cells: Angels or Demons? J Biomed Biotechnol. 2011;2011:459510.

[23] Hilfiker A, Kasper C, Hass R, et al. Mesenchymal stem cells and progenitor cells in connective tissue engineering and regenerative medicine: is there a future for transplantation? Langenbecks Arch Surg.2011;396(4):489-497.

[24] Ma XH, Feng K, Shi BY. Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu. 2011;15(32):6064-6067.马锡慧, 冯凯, 石炳毅. 人脐带间充质干细胞生物学特性及其研究进展[J]. 中国组织工程研究与临床康复,2011,15(32): 6064-6067.

[25] Moroni L, Fornasari PM. Human mesenchymal stem cells: A bank perspective on the isolation, characterization and potential of alternative sources for the regeneration of musculoskeletal tissues. J Cell Physiol. 2013;228(4):680-687.

[26] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317.

[27] Yang CC, Shih YH, Ko MH, et al. Transplantation of Human Umbilical Mesenchymal Stem Cells from Wharton's Jelly after Complete Transection of the Rat Spinal Cord. Plos One. 2008;3(10):e3336.